Shares of LENZ Therapeutics (LENZ) fell ~26% on Friday, a move TD Cowen attributed to investor worries over an adverse event reported on a federal database about the company’s newly launched eye ...

LENZ Therapeutics is rated HOLD as VIZZ’s commercial potential is highly dependent on uncertain consumer behavior, not medical necessity. LENZ’s current valuation reflects a base-case scenario where ...

Evert “Eef” Schimmelpennink is a busy guy. He’s the president and CEO of Lenz Therapeutics, a biopharmaceutical company in Solana Beach that recently rolled out a new product to treat the millions of ...

Jeffrey Lenz, 53, of Noblesville, Indiana, passed away peacefully on October 31, 2025, surrounded by his loved ones, following a brave battle with a glioblastoma brain tumor. He is survived by his ...

LENZ Therapeutics Inc (NASDAQ:LENZ) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $6.83 million, and the earnings are expected to come in at ...

The price trend for LENZ Therapeutics, Inc. (LENZ) has been bearish lately and the stock has lost 6.3% over the past week. However, the formation of a hammer chart pattern in its last trading session ...

LENZ Therapeutics, Inc. (LENZ) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Caroline Lenz McClure passed away peacefully in Stockton on September 8, 2025. Caroline was a Stocktonian and member of a pioneer agricultural family. She was the daughter of Howard Oliver Lenz and ...

Terry Lenz, a radio personality whose voice became the background to life in the Saginaw area for more than 25 years, died Wednesday, Aug. 6. He was 74. “There are so many great stories about Terry,” ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past efforts by other drug developers have mostly been unsuccessful. The ...

Vizz, an aceclidine-based eye drop, is FDA-approved for presbyopia, enhancing near vision without myopic shifts. Successful Phase III trials showed Vizz's efficacy and safety, with near vision ...

Lenz Therapeutics is a clinical-stage biotech aiming to reshape vision correction for presbyopia, an age-related loss of near vision affecting people over forty. Its lead product, LNZ100, is a ...